Forward-Looking Statements

This presentation includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, which involve a number of risks and uncertainties. These forward-looking statements include all matters that are not historical facts and, without limiting the foregoing, can be identified by the use of forward-looking terminology, including the terms “believe,” “estimate,” “project,” “anticipate,” “expect,” “seek,” “predict,” “continue,” “possible,” “intend,” “may,” “might,” “will,” “could,” “would” or “should” or, in each case, their negative, or other variations or comparable terminology. They appear in a number of places throughout this presentation and include statements regarding our intentions, beliefs or current expectations concerning, among other things, our product candidates, research and development and clinical trial plans, manufacturing plans, commercialization objectives, prospects, strategies, the industry in which we operate and potential collaborations. We derive many of our forward-looking statements from our operating budgets and forecasts, which are based upon many detailed assumptions. While we believe that our assumptions are reasonable, we caution that it is very difficult to predict the impact of known factors, and, of course, it is impossible for us to anticipate all factors that could affect our actual results. For a discussion of potential risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the “Risk Factors” section, as well as discussions of potential risks, uncertainties and other important factors, in our most recent filings with the Securities and Exchange Commission. All forward-looking statements included in this presentation represent our views as of the date hereof and should not be relied upon as representing our views as of any date subsequent to the date on the cover page of this presentation. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so.

No representation or warranty is made as to the accuracy or completeness of the information or analysis in this presentation.
Purpose-Built to Solve Duchenne Muscular Dystrophy (DMD)

Founded by those touched by Duchenne muscular dystrophy

We start with Duchenne patients and their unmet needs

We are addressing the full spectrum of disease, from the underlying genetic cause to symptom management
Solid Is Addressing the Full Spectrum of Duchenne

**CORRECTIVE THERAPIES**
Gene therapy to address the genetic cause of DMD
**SGT-001 Microdystrophin Gene Transfer**

**DISEASE UNDERSTANDING**
Biomarkers and endpoints to improve development

**DISEASE-MODIFYING THERAPIES**
Small molecules and biologics to address disease mechanisms

**ASSISTIVE DEVICES**
Technology to support mobility
Features of SGT-001 Microdystrophin Protein

- SGT-001 selection based on more than 30 years of research; confirmed through internal comparative analysis
- Uniquely contains the nNOS binding domain

Visual representation only.
Manufacturing

Producing SGT-001
Addressing the DMD Gene Therapy Supply Challenge

(HIGH PATIENT NEED) × (HIGH AVERAGE PATIENT WEIGHT) × (HIGH DOSES) = SIGNIFICANT SUPPLY NEEDS
GMP Manufacturing Process Currently Producing At Significant Volume

- Successfully scaled up to 250L in suspension and produced multiple batches
- Each 250L batch can dose multiple patients
- Utilizes proven, validated and widely-available standard bioreactors

CellSTACK®  HYPERStack®

Successful scale up to 250L suspension complete
SGT-001 Clinical Program

IGNITE DMD
SGT-001 Phase I/II Clinical Study: Current Status

Primary Endpoints:
- Safety
- SGT-001 microdystrophin expression at 12 months

Secondary Endpoints:
- Muscle function and strength
- Cardiac and respiratory function
- Muscle mass, area and composition (MRI)

Open-label treatment study
All new eligible subjects receive SGT-001
Enrollment ongoing
IGNITE DMD: Study Status/Updates

- **FEB 2019**: Preliminary 3-month muscle biopsy data for first 3 patients at SGT-001 starting dose (5E13 vg/kg)
- **MAR 2019**: Necessary steps completed to escalate dose of SGT-001 to 2E14 vg/kg
- **MAY 2019**
  - Announced first subject dosed in second cohort (2E14 vg/kg)
  - Clinical trial activities initiated at 2 additional sites
- **AUG 2019**
  - Protocol amendment completed
  - Second patient dosed at 2E14 vg/kg
- **2H 2019**: Data from second cohort (2E14 vg/kg) expected later this year
Thank you!

@SolidBioDMD
#TogetherWeAreSolid
#PatientPowered